Oncology
Cancer clinical trials
Studies of cancers and tumors of every type and site, from prevention to treatment. We’re tracking 20,349 recruiting studies in this area right now.
By phase
- Not applicable9,620
- Phase 24,438
- Phase 12,681
- Phase 1/Phase 21,656
- Phase 31,399
- Phase 2/Phase 3286
- Phase 4269
Top conditions
- Breast Cancer1,208
- Prostate Cancer649
- Cancer634
- Colorectal Cancer475
- Lung Cancer420
- Ovarian Cancer342
- Multiple Myeloma327
- Pancreatic Cancer288
- Gastric Cancer284
- Acute Myeloid Leukemia280
- Hepatocellular Carcinoma259
- Solid Tumor246
- Advanced Solid Tumor230
- Head and Neck Cancer227
- Cervical Cancer225
- Endometrial Cancer213
- Advanced Solid Tumors209
- Esophageal Cancer190
Leading sponsors
- M.D. Anderson Cancer Center458
- Fudan University306
- National Cancer Institute (NCI)294
- Memorial Sloan Kettering Cancer Center290
- Sun Yat-sen University275
- Mayo Clinic237
- City of Hope Medical Center146
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences145
- AstraZeneca132
- Ruijin Hospital129
Where studies are running
- California1,399
- Texas636
- Arizona505
- Florida438
- Alabama431
- New York405
- Massachusetts342
- Maryland329
- New Jersey275
- Pennsylvania234
Recruiting studies20,349 total
- NCT04645160RecruitingPhase 1/Phase 2
Tivozanib for bile duct and gallbladder cancers after chemotherapy
This Phase 1/2 trial tests tivozanib (a targeted anti-cancer drug) in people with bile duct or gallbladder cancer that cannot be removed by surgery and has already been treated with first-line chemotherapy. The study looks at how well the drug works and how safe it is in this setting.
Bethesda, MarylandAges 18 years+ - NCT04671667RecruitingPhase 2
Pembrolizumab vs chemo-radiation after surgery for recurrent head/neck cancer
This trial tests whether pembrolizumab (an immunotherapy drug) works better than the usual chemo plus radiation after surgery for cancer that has come back in the head and neck area. It may help reduce cancer returning or spreading by using your immune system, but eligibility depends on how the cancer came back and your prior treatments.
Birmingham, AlabamaAges 18–79 - NCT04616560RecruitingPhase 2
New drug for recurrent Wilms tumor, osteosarcoma, and DSRCT
This trial tests a targeted drug called trastuzumab deruxtecan for children and young adults with certain cancers that have come back or not responded to treatment. It may help if your tumor has not responded to standard therapies.
Birmingham, AlabamaAges 12–39 - NCT04633252RecruitingPhase 1/Phase 2
Study drug plus docetaxel and abiraterone for advanced prostate cancer
This trial tests a new targeted cancer drug (PDS01ADC) combined with standard treatments docetaxel and abiraterone for men with advanced prostate cancer that has spread. The goal is to see if the combination is safe and whether it can control cancer better than current approaches.
Bethesda, MarylandAges 18–110 - NCT04614103RecruitingPhase 2
Immune cell therapy for advanced lung cancer after chemotherapy
This trial studies LN-145, a treatment made from your own immune cells, for metastatic (stage IV) non-small-cell lung cancer. It may help shrink tumors after your cancer has progressed despite standard first-line chemotherapy and immunotherapy.
Gilbert, ArizonaAges 18–70 - NCT04641247RecruitingPhase 2
Long-term niraparib follow-up for people already benefiting
This study looks at continuing niraparib for a longer time in people who already finished an earlier niraparib trial and are still benefiting. It may help understand how safe and useful long-term treatment is for you.
Tucson, ArizonaAges 18 years+ - NCT04634357RecruitingPhase 1/Phase 2
Testing donor-like immune T cells for children with liver cancer
This Phase 1/2 trial tests an immune-cell treatment (ET140203 T cells) in children and teens with certain liver cancers that have come back or did not respond to standard treatment. It aims to see whether these T cells can shrink tumors and is mainly focused on safety and early effectiveness.
Los Angeles, CaliforniaAges 1–21 - NCT04634552RecruitingPhase 2
Talquetamab study for relapsed or refractory multiple myeloma
This trial studies talquetamab, a medicine given to treat multiple myeloma that has come back or did not respond to prior treatment. It may help shrink tumors and improve disease control, depending on how your myeloma measures and your health status.
Birmingham, AlabamaAges 18 years+ - NCT04683250RecruitingPhase 1/Phase 2
RET-targeting drug study for advanced cancers with RET changes
This trial tests an “RET-inhibitor” medicine (TAS0953/HM06) for advanced solid tumors that have RET gene changes. It may help shrink tumors by blocking cancer growth signals from the RET gene.
Orange, CaliforniaAges 18 years+ - NCT04613596RecruitingPhase 2/Phase 3
Adagrasib for KRAS G12C lung cancer, alone or with pembrolizumab
This trial studies adagrasib (an anti-cancer drug) either alone or with pembrolizumab (an immunotherapy) in people with advanced lung cancer that has a KRAS G12C mutation. It aims to shrink tumors and improve outcomes, including for people without urgent brain treatment needs.
Goodyear, ArizonaAges 18 years+ - NCT04617522RecruitingPhase 1
Sacituzumab govitecan for advanced cancers with moderate liver issues
This Phase 1 study tests how safe and tolerable sacituzumab govitecan is for people with advanced or metastatic solid tumors who also have moderate liver impairment. It aims to find the right dosing so the treatment can be used more safely in this liver-risk group.
Long Beach, CaliforniaAges 18 years+ - NCT04678648RecruitingPhase 1
Testing RSC-1255 in advanced cancers with RAS changes
This early study (Phase 1) tests a new drug, RSC-1255, in people with advanced or metastatic cancers that have RAS mutations. It’s mainly focused on whether the treatment can be given safely and at what dose, and to see if it may shrink tumors.
Los Angeles, CaliforniaAges 18 years+ - NCT04648462Recruiting
Proton therapy planning for certain brain tumors
This study builds and tests how proton therapy planning could better protect the brain compared with standard radiation (photon therapy) for adults with certain brain tumors. It may help reduce radiation to sensitive areas like the hippocampus, with the goal of better long-term brain function.
Maastricht, LimburgAges 18 years+ - NCT04664179RecruitingPhase 1
EBV immune-cell treatment for EBV-positive lymphoma
This Phase 1 study tests an immune-cell therapy made to recognize EBV (a common virus) in people whose lymphoma contains EBV. It may help control EBV-driven cancers, especially when standard treatment isn’t working or can’t be used.
Houston, TexasAges Any age - NCT04644952Recruiting
Study of robotic lung segment surgery outcomes
This study looks at people who had a lung surgery called a segmentectomy with robotic assistance in the past. It aims to understand how these surgeries are done over time and what outcomes result for patients.
Houston, TexasAges Any age - NCT04629677Recruiting
Portal vein stent for narrowed portal blood vessels
This trial looks at whether placing a small metal stent in the portal vein and nearby veins can improve problems caused by major narrowing (or clotting) of these vessels in people with gastrointestinal cancers. If you have significant vessel narrowing, the study may offer a targeted way to relieve pressure and symptoms that are not caused by the tumor directly.
Houston, TexasAges 18 years+ - NCT04598009RecruitingPhase 2
Binimetinib and imatinib for KIT-mutant advanced melanoma
This Phase 2 trial tests binimetinib plus imatinib in people with advanced melanoma that cannot be removed with surgery and that has a KIT mutation. It’s for melanoma that has gotten worse after standard treatment (or where standard treatment isn’t possible or tolerated).
La Jolla, CaliforniaAges 18 years+ - NCT04660435Recruiting
Study how breast cancers resist CDK4/6 inhibitor treatment
This study looks at why some ER-positive, HER2-negative metastatic breast cancers don’t respond well to CDK4/6 inhibitors combined with hormone therapy. It may help researchers understand resistance and improve future treatment choices for people like you.
Prato, TuscanyAges Any age - NCT04610372Recruiting
Targeted radiation plus hormone therapy for prostate cancer spread
This study compares different ways of giving radiation (SABR or brachytherapy) along with long-term hormone therapy for men whose prostate cancer has spread to a limited number of spots in the body. It aims to see which radiation approach controls the cancer as well as possible while keeping quality of life in mind.
Kelowna, British ColumbiaAges 18 years+ - NCT04683315RecruitingPhase 2
Pancreatic cancer biopsy-guided chemo before surgery
This trial uses a special gene test on fluid taken from an endoscopic ultrasound (EUS) biopsy to help choose chemotherapy before surgery for pancreas cancer. It aims to see if this approach improves outcomes by matching treatment to the tumor’s RNA pattern.
Scottsdale, ArizonaAges 18 years+ - NCT04611087Recruiting
Weight-loss program participants: self-monitoring focus group
This trial is looking to learn from people who finished a specific weight-loss program recently and ask them to share their experiences. The goal is to improve how weight-loss support and tracking work for participants.
Houston, TexasAges Any age - NCT04623931RecruitingPhase 2
Chemo and radiation for IDH-wildtype glioma
This Phase 2 study tests a combination of chemotherapy and radiation after surgery for certain brain tumors that are “IDH wildtype.” It aims to control the tumor and improve outcomes for people with specific types of glioma or glioblastoma.
Houston, TexasAges 18 years+ - NCT04613388Recruiting
Proton radiation registry study for adults with lymphoma
This study collects information about adults with lymphoma who need treatment that targets the chest/mediastinum. It focuses on how proton radiation may help protect the heart, lungs, and breast compared with the more common photon radiation.
HeidelbergAges 18 years+ - NCT04620187RecruitingPhase 2
Study medicine T-DM1 after surgery for HER2-positive salivary cancer
This Phase 2 trial studies T-DM1 given after surgery for salivary gland cancer that is HER2-positive. The goal is to reduce the risk of the cancer coming back by targeting HER2-positive tumor cells.
Atlanta, GeorgiaAges 18 years+
Common questions
- How many cancer clinical trials are recruiting?
- Clin2 is tracking 20,349 recruiting oncology studies from the U.S. registry right now, out of 31,598 we cover in this area in total.
- What does “Cancer” cover here?
- Studies of cancers and tumors of every type and site, from prevention to treatment. We group each study into cancer based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a cancer trial near me?
- Use the search to filter cancer studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Blood & lymphatic
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.